^
    Back
    Association details:
    Biomarker:PTEN deletion
    Cancer:HER2 Positive Breast Cancer
    Drug:Herceptin (trastuzumab) (HER2 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    J Buon
    Title:

    PTEN loss is a predictive marker for HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies

    Published date:
    01/02/2020
    Excerpt:
    We found that PTEN loss occurred in 43% of our study group and correlated with resistance to trastuzumab and shortened PFS.
    DOI:
    JBUON 2019; 24(5): 1920-1926
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Breast Cancer Res Treat
    Title:

    Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer

    Published date:
    05/19/2011
    Excerpt:
    PIK3CA mutations and/or PTEN loss status were evaluated together as a single parameter, to estimate the impact of activation of the PI3K/AKT molecular pathway, and it was significantly associated with both decreased TTP (P = 0.003 in the total population, P = 0.004 in HER2-positive patients) and survival (survivalT, P = 0.011 in total, P = 0.006 in HER2-positive).
    DOI:
    10.1007/s10549-011-1572-5